Loading...

Bionomics

ASX:BNO
Snowflake Description

Reasonable growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BNO
ASX
A$73M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. The last earnings update was 95 days ago. More info.


Add to Portfolio Compare Print
  • Bionomics has significant price volatility in the past 3 months.
BNO Share Price and Events
7 Day Returns
-16.1%
ASX:BNO
-4.6%
AU Biotechs
-3.3%
AU Market
1 Year Returns
-67.9%
ASX:BNO
29.4%
AU Biotechs
2.5%
AU Market
BNO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bionomics (BNO) -16.1% -21.2% -73.7% -67.9% -73.5% -82.7%
AU Biotechs -4.6% -2.8% -13.7% 29.4% 88.8% 177.7%
AU Market -3.3% -3.3% -6.8% 2.5% 40.1% 51.1%
1 Year Return vs Industry and Market
  • BNO underperformed the Biotechs industry which returned 29.4% over the past year.
  • BNO underperformed the Market in Australia which returned 2.5% over the past year.
Price Volatility
BNO
Industry
5yr Volatility vs Market

Value

 Is Bionomics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Bionomics. This is due to cash flow or dividend data being unavailable. The share price is A$0.13.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bionomics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bionomics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:BNO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in AUD A$-0.05
ASX:BNO Share Price ** ASX (2018-11-19) in AUD A$0.13
Global Biotechs Industry PE Ratio Median Figure of 73 Publicly-Listed Biotechs Companies 26.19x
Australia Market PE Ratio Median Figure of 555 Publicly-Listed Companies 15.66x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bionomics.

ASX:BNO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:BNO Share Price ÷ EPS (both in AUD)

= 0.13 ÷ -0.05

-2.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bionomics is loss making, we can't compare its value to the Global Biotechs industry average.
  • Bionomics is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Bionomics's expected growth come at a high price?
Raw Data
ASX:BNO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
39.3%per year
Global Biotechs Industry PEG Ratio Median Figure of 53 Publicly-Listed Biotechs Companies 1.27x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bionomics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bionomics's assets?
Raw Data
ASX:BNO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in AUD A$0.04
ASX:BNO Share Price * ASX (2018-11-19) in AUD A$0.13
Australia Biotechs Industry PB Ratio Median Figure of 45 Publicly-Listed Biotechs Companies 3.59x
Australia Market PB Ratio Median Figure of 1,639 Publicly-Listed Companies 1.77x
ASX:BNO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:BNO Share Price ÷ Book Value per Share (both in AUD)

= 0.13 ÷ 0.04

3.7x

* Primary Listing of Bionomics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bionomics is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Bionomics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Bionomics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Bionomics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bionomics expected to grow at an attractive rate?
  • Bionomics's earnings growth is expected to exceed the low risk savings rate of 2.8%.
Growth vs Market Checks
  • Bionomics's earnings growth is expected to exceed the Australia market average.
  • Bionomics's revenues are expected to decrease over the next 1-3 years, this is below the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:BNO Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:BNO Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 39.3%
ASX:BNO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts -2.3%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 10.8%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 8%
Australia Market Earnings Growth Rate Market Cap Weighted Average 7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:BNO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:BNO Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 12 -8 -9 2
2020-06-30 25 17 -11 2
2019-06-30 27 27 17 3
ASX:BNO Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-06-30 12 -20 -25
2018-03-31 19 -16 -15
2017-12-31 27 -11 -6
2017-09-30 27 -6 -6
2017-06-30 27 -1 -7
2017-03-31 22 -7 -12
2016-12-31 16 -13 -17
2016-09-30 18 -14 -17
2016-06-30 19 -15 -17
2016-03-31 19 -17 -19
2015-12-31 18 -18 -21
2015-09-30 17 -6 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Bionomics's earnings are expected to grow significantly at over 20% yearly.
  • Bionomics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:BNO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Bionomics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:BNO Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 -0.02 -0.02 -0.02 1.00
2020-06-30 -0.02 0.02 -0.06 2.00
2019-06-30 0.04 0.06 0.03 3.00
ASX:BNO Past Financials Data
Date (Data in AUD Millions) EPS *
2018-06-30 -0.05
2018-03-31 -0.03
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.02
2016-12-31 -0.03
2016-09-30 -0.04
2016-06-30 -0.04
2016-03-31 -0.04
2015-12-31 -0.05
2015-09-30 -0.04

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Bionomics is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Bionomics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bionomics has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Bionomics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bionomics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bionomics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Bionomics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bionomics's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Bionomics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bionomics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:BNO Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 11.88 -25.09 6.76
2018-03-31 19.48 -15.49 7.28
2017-12-31 27.08 -5.90 6.93
2017-09-30 27.06 -6.32 7.19
2017-06-30 27.05 -6.75 8.32
2017-03-31 21.60 -11.67 10.25
2016-12-31 16.16 -16.60 12.18
2016-09-30 17.69 -16.60 11.37
2016-06-30 19.23 -16.59 10.56
2016-03-31 18.62 -18.78 9.92
2015-12-31 18.01 -20.96 9.27
2015-09-30 16.57 -18.96 8.93
2015-06-30 15.13 -16.95 8.59
2015-03-31 22.16 -6.29 6.68
2014-12-31 29.20 4.37 4.78
2014-09-30 28.09 3.79 4.69
2014-06-30 26.98 3.21 4.59
2014-03-31 19.26 -4.80 4.99
2013-12-31 11.54 -12.80 5.39
2013-09-30 11.68 -11.40 5.16
2013-06-30 11.83 -10.00 4.94
2013-03-31 12.55 -6.86 4.64
2012-12-31 13.28 -3.71 4.35
2012-09-30 11.61 -3.42 4.04
2012-06-30 9.94 -3.14 3.73
2012-03-31 6.91 -5.71 3.36
2011-12-31 3.88 -8.29 2.98

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bionomics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Bionomics has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bionomics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Bionomics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bionomics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Bionomics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bionomics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bionomics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bionomics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bionomics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bionomics Company Filings, last reported 4 months ago.

ASX:BNO Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 16.96 21.43 24.93
2018-03-31 16.96 21.43 24.93
2017-12-31 31.51 20.13 32.57
2017-09-30 31.51 20.13 32.57
2017-06-30 40.45 18.51 42.87
2017-03-31 40.45 18.51 42.87
2016-12-31 36.19 21.69 43.67
2016-09-30 36.19 21.69 43.67
2016-06-30 44.16 21.17 45.45
2016-03-31 44.16 21.17 45.45
2015-12-31 49.40 18.91 51.41
2015-09-30 49.40 18.91 51.41
2015-06-30 31.97 14.78 26.56
2015-03-31 31.97 14.78 26.56
2014-12-31 40.49 13.62 38.37
2014-09-30 40.49 13.62 38.37
2014-06-30 44.82 1.29 9.57
2014-03-31 44.82 1.29 9.57
2013-12-31 35.63 1.02 20.47
2013-09-30 35.63 1.02 20.47
2013-06-30 41.41 1.08 22.45
2013-03-31 41.41 1.08 22.45
2012-12-31 29.78 1.09 9.29
2012-09-30 29.78 1.09 9.29
2012-06-30 25.90 1.18 17.37
2012-03-31 25.90 1.18 17.37
2011-12-31 25.30 1.09 17.89
  • Bionomics's level of debt (126.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (2.6% vs 126.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Bionomics has sufficient cash runway for 2.7 years based on current free cash flow.
  • Bionomics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 16.5% each year.
X
Financial health checks
We assess Bionomics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bionomics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Bionomics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bionomics dividends. Estimated to be 0% next year.
If you bought A$2,000 of Bionomics shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bionomics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bionomics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:BNO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 22 Stocks 2.2%
Australia Market Average Dividend Yield Market Cap Weighted Average of 420 Stocks 4.6%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.6%
Australia Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:BNO Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30
2020-06-30
2019-06-30 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bionomics has not reported any payouts.
  • Unable to verify if Bionomics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bionomics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bionomics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Bionomics's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Bionomics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bionomics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bionomics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Bionomics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Deborah Rathjen
COMPENSATION A$591,742
AGE 60
CEO Bio

Dr. Deborah Ann Rathjen, B.Sc. (Hons.), Ph.D., M.A.I.C.D., FTSE, Q.C. serves as the Chief Executive Officer of Bionomics Limited. Dr. Rathjen was an Executive Director at Bionomics Ltd. since May 18, 2000 until November 09, 2018. She was Managing Director of Bionomics Limited until November 9, 2018. Dr. Rathjen has proven to be a skilled dealmaker and builder of alliances with her work on the Bionomics and Merck collaborations related to Alzheimer's disease and other neurodegenerative and psychiatric diseases with the goal to improve cognitive dysfunction in neurodegeneration. She has significant experience in company building and financing, mergers and acquisitions, therapeutic product research and development, business development, licensing and commercialization. She has experience in research, business development and licensing and licensing and has licensed a range of products including drug delivery technologies, diagnostics, new therapeutics and cosmetic products. Dr. Rathjen joined Bionomics in June 2000 from Peptech Limited, where she was General Manager of Business Development and Licensing. She also serves as Chief Executive Officer at Prestwick Chemical, Inc. since October 2014. Dr. Rathjen was a co-inventor of Peptech's TNF technology and leader of its successful defence of its key TNF patents against a legal challenge by BASF, providing Peptech with a strong commercial basis for licensing negotiations with BASF, Centocor and other companies with anti-TNF products. Dr. Rathjen is an expert in the field of cell biology with specific expertise in inflammation and cancer. She has been Chair of the Board of biOasis Technologies Inc. since March 21, 2018 and as its Director since September 21, 2017. Dr. Rathjen is a member of the Federal Government's Australian Biotechnology Advisory Council and the Prime Minister's Science Engineering and Innovation Council. In 2004, she was awarded the AusBiotech President’s Medal for her significant contribution to the Australian biotechnology industry. In 2006 Dr. Rathjen received a Distinguished Alumni Award from Flinders University, in 2009 the BioSingapore Asia Pacific Woman Entrepreneur of the Year, 2010 Bio Innovation SA Industry Leader Award, BioSpectrum Asia Person of the Year 2013 and in 2014 the Life Science Woman of the Year. Dr. Rathjen received her doctor of philosophy degree in immunology from Macquarie University in Sydney, Australia and her bachelor of science degree in immunology from Flinders University in Adelaide, Australia.

CEO Compensation
  • Deborah's compensation has increased whilst company is loss making.
  • Deborah's remuneration is higher than average for companies of similar size in Australia.
Management Team

Errol De Souza

TITLE
Executive Chairman
COMPENSATION
A$136K
AGE
65

Deborah Rathjen

TITLE
Chief Executive Officer
COMPENSATION
A$592K
AGE
60

Steve Lydeamore

TITLE
Chief Financial Officer
COMPENSATION
A$493K
TENURE
1.3 yrs

Jack Moschakis

TITLE
Legal Counsel & Company Secretary
COMPENSATION
A$387K
TENURE
3.5 yrs

Paul Rolan

TITLE
Consultant Medical Officer of Clinical Neuroscience
COMPENSATION
A$80K
Board of Directors Tenure

Average tenure and age of the Bionomics board of directors in years:

2.2
Average Tenure
65
Average Age
  • The average tenure for the Bionomics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Errol De Souza

TITLE
Executive Chairman
COMPENSATION
A$136K
AGE
65
TENURE
2.2 yrs

Peter Turner

TITLE
Non-Executive Director
COMPENSATION
A$78K
AGE
69
TENURE
2.4 yrs

Alan Fisher

TITLE
Non-Executive Director
COMPENSATION
A$80K
AGE
64
TENURE
2.2 yrs

Tim Harris

TITLE
Scientific Advisor
AGE
67
TENURE
2.2 yrs

Paul Fitzgerald

TITLE
Scientific Advisor

Ann Hayes

TITLE
Scientific Advisor

Fiona McLaughlin

TITLE
Scientific Advisor
AGE
48

José Iglesias

TITLE
Scientific Advisor
COMPENSATION
A$151K
TENURE
2.8 yrs

Philippe Danjou

TITLE
Scientific Advisor

Richard Hargreaves

TITLE
Scientific Advisor
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
05. Oct 18 Sell New York Life Investment Management LLC Company 12. Mar 18 03. Oct 18 -30,274,065 A$0.12 A$-3,767,745
05. Oct 18 Buy New York Life Investment Management LLC Company 06. Mar 18 19. Sep 18 7,255,897 A$0.52 A$3,749,068
14. Jun 18 Sell Private Portfolio Managers Company 21. Feb 18 07. Jun 18 -587,209 A$0.60 A$-291,330
14. Jun 18 Buy Private Portfolio Managers Company 09. Feb 18 30. May 18 208,634 A$0.58 A$109,446
05. Mar 18 Sell New York Life Investment Management LLC Company 29. Jun 17 22. Nov 17 -7,021,674 A$0.42 A$-2,963,012
05. Mar 18 Buy New York Life Investment Management LLC Company 29. Mar 17 01. Mar 18 12,398,963 A$0.41 A$5,052,969
X
Management checks
We assess Bionomics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bionomics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Does Market Volatility Impact Bionomics Limited's (ASX:BNO) Share Price?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

Who Owns Most Of Bionomics Limited (ASX:BNO)?

In this analysis, my focus will be on developing a perspective on Bionomics Limited’s (ASX:BNO) latest ownership structure, a less discussed, but important factor. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.

Simply Wall St -

Analysts Expect Breakeven For Bionomics Limited (ASX:BNO)

The AU$260.70m market-cap company’s loss lessens since it announced a -AU$6.75m bottom-line in the full financial year, compared to the latest trailing-twelve-month loss of -AU$5.90m, as it approaches breakeven? … I’ve put together a brief outline of industry analyst expectations for BNO, its year of breakeven and its implied growth rate … According to the industry analysts covering BNO, breakeven is near.

Simply Wall St -

When Can We Expect A Profit From Bionomics Limited (ASX:BNO)?

In this article, I will touch on the expectations for BNO’s growth and when analysts expect the company to become profitable. … Working backwards from analyst estimates, it turns out that they expect the company to grow 92.12% year-on-year, on average, which signals high confidence from analysts. … Next Steps: There are too many aspects of BNO to cover in one brief article, but the key fundamentals for the company can all be found in one place – BNO’s company page on Simply Wall St.

Simply Wall St -

Company Info

Map
Description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company’s product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Details
Name: Bionomics Limited
BNO
Exchange: ASX
Founded: 1998
A$73,309,698
543,034,805
Website: http://www.bionomics.com.au
Address: Bionomics Limited
31 Dalgleish Street,
Thebarton,
South Australia, 5031,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX BNO Ordinary Shares Australian Securities Exchange AU AUD 21. Dec 1999
OTCPK BNOE.F Ordinary Shares Pink Sheets LLC US USD 21. Dec 1999
DB B1N Ordinary Shares Deutsche Boerse AG DE EUR 21. Dec 1999
BST B1N Ordinary Shares Boerse-Stuttgart DE EUR 21. Dec 1999
CHIA BNO Ordinary Shares Chi-X Australia AU AUD 21. Dec 1999
Number of employees
Current staff
Staff numbers
0
Bionomics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2018/11/19 07:58
End of day share price update: 2018/11/19 00:00
Last estimates confirmation: 2018/11/11
Last earnings filing: 2018/08/16
Last earnings reported: 2018/06/30
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.